Daiichisankyo.com

Daiichi Sankyo. Develops and delivers new standards of care to enrich the quality of life around the world.

What’s new on Daiichisankyo.com: Check updates and related news right now. This site’s feed is stale or rarely updated (or it might be broken for a reason), but you may check related news or Daiichisankyo.com popular pages instead. It is generally safe for browsing, so you may click any item to proceed to the site.

News, stories and media buzz related to Daiichi Sankyo

Subscribe to related news

New Tx Approved for VTE, Stroke Risk Reduction
via productdirectory.empr

Daiichi Sankyo announced that the FDA has approved Savaysa (edoxaban) tablets to reduce the risk of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF), and for the treatment of deep vein thrombosis (DVT) and pulmonary...
Daiichi Sankyo's Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Princ...
via altnews

- Once-daily edoxaban, evaluated in two treatment arms (60 mg and 30 mg), achieved the primary endpoint of non-inferior efficacy versus warfarin in the prevention of stroke or systemic embolism - Rates of major bleeding were significantly reduced with...
Daiichi Sankyo announces company acquistion of Ambit Biosciences
via currentpartnering

Daiichi Sankyo and Ambit Biosciences announced the company acquisition of the Ambit in a deal valued up to $410 million.Daiichi will acquire all outstanding Ambit stock for $15 per share, about $315 million, and merge with a Daiichi subsidiary. Ambit...
Ranbaxy Suspends API Shipments from Two Plants in India
via cbinet

Daiichi Sankyo announces suspension of API shipments from Ranbaxy?s Toansa and Dewas plants; issues apology to stakeholders. Published Date: February 24, 2014 URL: http://www.pharmtech.com/pharmtech/GMPs%2FValidation+News/Ranbaxy-Suspends...
CS 3150, angiotensin II receptor antagonist, for the treatment or prevention of such hypertension and heart disease
via newdrugapprovals.wordpress

CS-3150, (XL550) CS 3150, angiotensin II receptor antagonist, for the treatment or prevention of such hypertension and heart disease similar to olmesartan , losartan, candesartan , valsartan, irbesartan, telmisartan, eprosartan, Cas name 1H-Pyrrole...

Daiichisankyo.com popular pages

Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company based in Japan underpinned by its Purpose: “To contribute to the enrichment of quality of life around the world”.
CSR (Corporate Social Responsibility) - About Us - Daiichi Sankyo

Daiichi Sankyo, About Us, Responsibility, CSR (Corporate Social Responsibility)